Repligen Co. (NASDAQ:RGEN) Director Thomas F. Ryan, Jr. sold 1,763 shares of the stock in a transaction on Monday, November 5th. The shares were sold at an average price of $65.75, for a total value of $115,917.25. Following the completion of the transaction, the director now owns 3,225 shares of the company’s stock, valued at approximately $212,043.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of Repligen stock opened at $67.91 on Wednesday. The stock has a market capitalization of $2.90 billion, a P/E ratio of 98.42, a price-to-earnings-growth ratio of 5.22 and a beta of 0.74. Repligen Co. has a 1 year low of $29.56 and a 1 year high of $68.50.
Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, November 1st. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.02. The firm had revenue of $49.53 million during the quarter, compared to the consensus estimate of $46.69 million. Repligen had a return on equity of 5.39% and a net margin of 12.61%. The business’s revenue for the quarter was up 35.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.15 EPS. As a group, analysts predict that Repligen Co. will post 0.72 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in the stock. Lisanti Capital Growth LLC lifted its stake in Repligen by 55.7% in the 3rd quarter. Lisanti Capital Growth LLC now owns 44,405 shares of the biotechnology company’s stock worth $2,463,000 after acquiring an additional 15,880 shares in the last quarter. American Capital Management Inc. purchased a new stake in Repligen in the 3rd quarter worth about $3,866,000. Victory Capital Management Inc. raised its stake in shares of Repligen by 56.7% during the 3rd quarter. Victory Capital Management Inc. now owns 10,451 shares of the biotechnology company’s stock worth $580,000 after purchasing an additional 3,781 shares in the last quarter. Ardevora Asset Management LLP purchased a new stake in shares of Repligen during the 3rd quarter worth about $5,937,000. Finally, Arizona State Retirement System raised its stake in shares of Repligen by 3.3% during the 3rd quarter. Arizona State Retirement System now owns 56,556 shares of the biotechnology company’s stock worth $3,137,000 after purchasing an additional 1,818 shares in the last quarter. 93.08% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently weighed in on RGEN shares. Stephens increased their price target on Repligen from $50.00 to $55.00 and gave the company an “average” rating in a research report on Tuesday, July 10th. BidaskClub lowered Repligen from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Citigroup increased their price target on Repligen from $45.00 to $56.00 and gave the company a “buy” rating in a research report on Friday, July 20th. Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $62.00 price target for the company in a research report on Thursday, October 4th. Finally, Janney Montgomery Scott reiterated a “buy” rating on shares of Repligen in a research report on Thursday, October 4th. Three equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. Repligen presently has a consensus rating of “Buy” and a consensus price target of $59.33.
WARNING: “Repligen Co. (RGEN) Director Thomas F. Ryan, Jr. Sells 1,763 Shares” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/11/07/repligen-co-rgen-director-thomas-f-ryan-jr-sells-1763-shares.html.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Story: Treasury Bonds
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.